• Imunon posted preliminary Phase 2 MRD data for IMNN-001 in newly diagnosed advanced ovarian cancer, supporting its ongoing Phase 3 OVATION 3 trial.
• Second-look laparoscopy showed lower MRD-positive rates with IMNN-001 vs control: 44% vs 67%; ctDNA clearance 87.5% vs 62.5%.
• Safety remained favorable, with no cytokine release syndrome, systemic toxicities, or serious immune-related adverse events reported to date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imunon Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607210900PRIMZONEFULLFEED9765335) on July 21, 2026, and is solely responsible for the information contained therein.